You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Osteoporosis

Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

  • Technology appraisal guidance
  • Reference number: TA161
  • Published:  27 October 2008
  • Last updated:  07 February 2018
  • Guidance
  • Tools and resources
  • History

TA161 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix C - Decision Support Unit Report

TA161 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix C - Decision Support Unit Report TA161 Technologies for the primary and secondary prevention of osteoporotic fractures: Appendix C - Decision Support Unit Report
27 August 2013
(559.88 Kb 43 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 23 August 2013

Back to top